Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

NCT04392154 PHASE3 COMPLETED Results posted

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Details

Lead sponsor	Eli Lilly and Company
Phase	PHASE3
Status	COMPLETED
Enrolment	1153
Start date	Mon Jun 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Atopic Dermatitis

Interventions

• Lebrikizumab

Countries

France, Ukraine, Taiwan, Estonia, Germany, Poland, Mexico, South Korea, Canada, Lithuania, Bulgaria, Australia, Singapore, United States, Spain, Latvia